Industry Symposia at ECP 2023

Room: Liffey Hall 2

Chair: Michael Hubank
Speakers: Jeroen Van Der Laak | Michael Hubank | Arndt Hartmann

Welcome and Introduction

Michael Hubank, United Kindgom

Keynote: Emerging role of digital pathology in breast cancer

Jeroen Van Der Laak, The Netherlands

Update on decentralised genomic instability testing in ovarian cancer

Michael Hubank, United Kindgom

What’s next for prostate cancer diagnostics?

Arndt Hartmann, Germany

Q&A and Close

Michael Hubank, United Kindgom

Room: Liffey B (also available as live stream and on-demand)

Chair: Frederique Penault-Llorca
Speakers: Christian Jackisch | Caterina Marchio | Roberto Salgado

Welcome and Introduction

Frederique Penault-Llorca, France

Working together: What do Oncologists need from Pathologists?

Christian Jackisch, Germany

A new era of breast cancer testing: Key practical considerations

Caterina Marchio, Italy

Looking to the future: How can new technologies assist us to better assess HER2? 
Roberto Salgado, Belgium

Interactive discussion and Wrap up
All faculty

Room: Wicklow Hall 2 (also available as live stream and on-demand)

Co-Chair: Eva Compérat | Henning Reis
Speakers: Eva Compérat | Henning Reis | Ray McDermott

Welcome and introductions

Eva Compérat, Austria | Henning Reis, Germany

Precision medicine in genitourinary cancers: Clinical landscape and new data

Ray McDermott, Ireland

Precision medicine: Utilising biomarker testing in bladder and prostate cancer

Eva Compérat, Austria | Henning Reis, Germany

Pathologist recap – Interactive Q&A

All faculty

Patient case: Addressing the diagnostic challenges of bladder cancer

Eva Compérat, Austria

Interactive Q&A

All faculty

Room: Wicklow Hall 1

Chair: Marilyn Bui 
Speakers: Reinhard Büttner | Nicola Normanno  | Marilyn Bui

Welcome and Introduction 
Marilyn Bui, USA 
An Overview of recent advances in IO therapies and the role of PD-L1 as a biomarker
Reinhard Büttner, Germany 
Clinical utility of ctDNA: current role and emerging applications 
Nicola Normanno, Italy

Clinical Utilization of digital pathology: Are we there yet?

Marilyn Bui, USA
Panel discussion: navigating the institutional integration and Implementation of newer diagnostic technologies and audience Q&A 
All faculty
Closing remarks 
Marilyn Bui, USA

Room: Liffey Hall 2

Chair: John Longshore
Speakers: Alexandre Harlé | Elena Provenzano

Welcome and Introduction
John Longshore, USA 
Liquid biopsy in breast cancer:
practical applications and potential utility

Alexandre Harlé, France 
Discussion and Q&A 
All faculty 
Digital and computational pathology:
integration into breast cancer diagnostics
Elena Provenzano, United Kingdom 
Discussion and Q&A 
All faculty

Room: Liffey A

Chair: Emilia Andersson
Speakers: Magali Lacroix-Triki | Nadim Habib | Federico Rojo Todo

Opening remarks 

Emilia Andersson, Sweden

Pragmatic view of navigating in the evolving breast cancer landscape

Magali Lacroix-Triki, France

How to optimize patients outcome and manage costs in precision diagnostics

Nadim Habib, Portugal

Getting it right in the lab and in the clinic: the importance of analytical and clinical validation

Federico Rojo Todo, Spain

Interactive discussion

All faculty

Room: Liffey Hall 1

Chair: Jessica Baumann
Speakers: Christian Eisen | Bethany Williams

Welcome and Introduction 
Jessica Baumann, USA 
Quantitative Continous Scoring: a new frontier in diagnostics
Christian Eisen, Germany 
Discussion and Q&A

All faculty

Pathology at the frontier: preparing for new opportunities in practice
Bethany Williams, United Kingdom 
Discussion and Q&A
All faculty

Room: Wicklow Hall 1

Chair: Philippe Menu
Speakers: Alex Tuck | Maria De Bonis | Dolors Colomer

Decentralizing collective intelligence in precision oncology
Alex Tuck, Switzerland

Analytical performance of CNV calling prototype for Homologous Recombination Deficiency (HRD) detection

Maria De Bonis, Italy
The impact of NGS molecular profiling in Chronic Lymphocytic Leukemia (CLL) 
Dolors Colomer, Spain

Room: Liffey A

Chair: Javier Hernandez Losa | Francesco Passiglia
Speakers: Annette Staebler | Réiltín Werner | Gorka Alkorta | Simonetta Buglioni

Welcome and Introduction
Javier Hernandez Losa, Spain | Francesco Passiglia, Italy
ISO15189 Next generation gequencing testing at Cork University Hospital

Réiltín Werner, Ireland

Feasibility study: comparing tissue and blood profiles at baseline for the identification of genomic alterations

Simonetta Buglioni, Italy

Exploring the Impact of comprehensive genomic profiling in solid tumor testing

Gorka Alkorta, Spain

Ovarian cancer testing: unveil Homologous Recombination Deficiency (HRD) through CGP NGS analysis 
Annette Staebler, Germany 

Q&A

All faculty

 

Room: Wicklow Hall 1 (also available as on-demand)

Chair: Caterina Marchiò | Nicola Normanno
Speakers: Caterina Marchiò | Csaba Bödör | Nicola Normanno | Robert Haddad

Welcoming Remarks
Caterina Marchiò, Italy
Nicola Normanno, Italy  
Value of CGP in Routine Clinical Practice

Caterina Marchiò, Italy

Csaba Bödör, Hungary

Importance of Early Testing and Treatment for Optimal Patient Care

Nicola Normanno, Italy

Robert Haddad, USA

Strategies to Implement CGP Routinely, Including Rare Biomarkers

All faculty

Closing Remarks

Caterina Marchiò, Italy

Nicola Normanno, Italy

Room: Liffey B (also available as live stream on-demand)

Chair:  Umberto Malapelle
Speakers: Dearbhaile Collins |  Umberto Malapelle | Léon van Kempen | Ana Peixoto

NSCLC, the frontrunner in precision medicine
Dearbhaile Collins, Ireland 
Molecular tumour board goes live: Multidisciplinary discussion of NSCLC patient cases

Case 1: NGS/CGP Testing Takes the Lead: Unveiling the Benefits Over Single Gene Testing

Case 2: Liquid Biopsy: Tracking Progression and Complex Variants Interpretation

All faculty

Panel Discussion: Paving the Way: Genomic Testing Access & Future Developments

All faculty

Room: Liffey Hall 2 (also available as live stream)

Chair: Frédérique Penault-Llorca
Speakers: Frédérique Penault-Llorca | Glenn McCluggage | Angela George

Introduction to early biomarker testing in
gynaecological cancers
Frédérique Penault-Llorca, France
Beyond TCGA classification: How biomarker
testing is evolving in endometrial cancer
Glenn McCluggage, United Kingdom
How biomarker testing translates to clinical
practice: Endometrial cancer
(Panel discussion – All Faculty)
Angela George, United Kingdom
The importance of testing early: Using
biomarkers to guide therapeutic decisions
in ovarian cancer
Frédérique Penault-Llorca, France
How biomarker testing translates to clinical
practice: Ovarian cancer
(Panel discussion – All Faculty)

Angela George, United Kingdom

Room: Wicklow Hall 2 

Chair: Béla Molnár
Speakers: Yoseph Chong | Arkadiusz Gertych | Laszlo Igali

Harnessing Digital Cytopathology for Enhanced Quality Assurance

Yosep Chong, South Korea

Can multilayer slide scanning improve AI-based identification of acid-fast mycobacteria in whole slide images?

Arkadiusz Gertych, USA

Threading it together - the power of the end-to-end solution in digital pathology

Laszlo Igali, United Kingdom

Room: Liffey Hall 2 (also available on-demand)

Co-Chairs / Speakers: Nicola Fusco | Fabio Pagni | Matteo Fassan | Umberto Malapelle

4oncommunity from vision to reality:
why this, why now?
Nicola Fusco, Italy
4oncommunity in action: an interactive
experience
Fabio Pagni, Italy
4oncommunity in context: the evolving
landscape of predictive molecular pathology
Matteo Fassan, Italy
4-ward to the future: what’s on the horizon?
Umberto Malapelle, Italy

Room: Liffey Hall 1 (also available on-demand)

Chair: Maria Vittoria Traversa
Speaker: Sophie Prevot

Room: Wicklow Hall 2 (also available as live stream on-demand)

Chair: Nicole van Grieken
Speakers: Maeve Lowery | Nicole van Grieken | Albrecht Stenzinger

Welcome and introductions
Nicole van Grieken, The Netherlands
Clues to the exit: Biomarkers in the treatment of G/GEJ adenocarcinoma
Maeve Lowery, Ireland
Revealing a clear path: Achieving onsistency
in biomarker testing
Nicole van Grieken, The Netherlands
Navigating the day-to-day changes and
challenges of the IVDR
Albrecht Stenzinger, Germany
Are we ready for action? 
All Faculty
Q&A session
All Faculty
Symposium summary and close
Nicole van Grieken, The Netherlands

Room: Liffey Hall 2 

Chair: Alexander Yarunin
Speakers: M. Angeles Montero Fernandez | Alexander Yarunin | David Gonzalez de Castro

Welcome and introduction
Alexander Yarunin, United Kingdom
Early-stage lung cancer diagnostic testing
including pathologic complete response
M. Angeles Montero Fernandez, United
Kingdom
Discussion and Q&A 
All Faculty
ctDNA: diagnostics applications across the
lung cancer care continuum
David Gonzalez de Castro, United Kingdom
Discussion and Q&A 
All Faculty

Room: Liffey Hall 1 (also available as live stream on-demand)

Chair: Martin F. Dietrich
Speakers: Shirley M. Shiller | Martin F. Dietrich

Welcome, Introductions, Pre-Session Survey
Martin F. Dietrich, USA
Targeting CEACAM5 in NSCLC: Clinical
Rationale and Testing Strategies
Speaker tbd

Clinical Validation of CEACAM5 as a
Therapeutic Target
Shirley M. Shiller, USA
Panel Discussion
All Faculty
Question and Answer Session
Martin F. Dietrich, USA

Room: Wicklow Hall 1 (also available as on-demand)

Chair: Alan Byrne
Speakers: Neil Ryan | James Blackwood | Shawn Kinsey | Paul Van Diest | Alan Byrne

Welcome & Agilent Digital Pathology Focus
Alan Byrne, Ireland
How digital pathology has enabled the scale
up of a novel capsule sponge test in the upper GI pathway
Neil Ryan, United Kingdom
The need for an open digital pathology
platform based on experiences at NHS GGC
James Blackwood, United Kingdom
Implementation and validation of a digital
pathology IMS and AI algorithm solution for
PD-L1 in a reference lab environment
Shawn Kinsey, USA
AI for accurate quantitation of therapeutic
targets
Paul Van Diest, The Netherlands
Panel Discussion
All Faculty

Room: Liffey A (also available as on-demand)

Chair: Arndt Hartmann
Speakers: Andrew Dodson | Arndt Hartmann | Søren Nielsen

Welcome and introduction
Arndt Hartmann, Germany
The state of PD-L1 testing in NSCLC: what
does the external quality assessment data
show? UK NEQAS perspective
Andrew Dodson, United Kingdom
The state of PD-L1 testing in gastric and
bladder cancer: what does the external
quality assessment data show? The Quality
in Pathology (QuIP) GmbH perspective
Arndt Hartmann, Germany
NordiQC: results and experiences learned
for PD-L1 biomarker testing
Søren Nielsen, Denmark
Q&A

All Faculty